Overview

• Enovis Q3 sales grow 9%, beating analyst expectations

• Adjusted EPS for Q3 beats consensus

• Company raises full-year 2025 adjusted EBITDA and EPS guidance

Outlook

• Enovis expects 2025 revenue between $2.24 bln and $2.27 bln

• Revenue guidance adjusted due to $15 mln reduction from Dr. Comfort divestitur

• Company raises full-year 2025 adjusted EBITDA guidance to $395-405 mln

• Enovis increases full-year 2025 adjusted EPS guidance to $3.10-3.25

Result Drivers

• RECONSTRUCTIVE SALES - Reconstructive sales grew 12% year-over-year, driven by stable markets and new product momentum

• GOODWILL IMPAIRMENT - Net loss impacted by a $548 mln non-cash goodwill impairment charge in Recon and P&R units

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for Enovis Corp is $52.50, about 40% above its November 5 closing price of $31.49

Press Release: ID:nGNX6x2q7w

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)